Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News  >  Companies  >  All News

News : Companies

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors

Zogenix Inc. : Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/03/2013 | 02:40pm CET
Conference Call Scheduled for May 9, 2013 at 4:30 pm ET

SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 318-8616 (U.S.) or (617) 399-5135 (International); participant passcode: 65838569.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning May 9, 2013 at 6:30 p.m. ET (3:30 p.m. PT) until May 16, 2013, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 23471504. A replay of the webcast will also be accessible on the Investor Relations website for one month, through June 9, 2013.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012. For additional information, please visit www.zogenix.com.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | [email protected]

         MEDIA:
         Caitlin Cox | The Ruth Group
         646.536.7033 | [email protected]
Zogenix
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news "Companies"
12:59p SugarHouse GM Wendy Hamilton to Receive 2018 Paradigm Award
12:59p BONE BIOLOGICS : Financial Statements and Exhibits (form 8-K/A)
12:58p PHASERX, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits (form 8-K)
12:58p ITAFOS : Announces Update on Non Brokered Private Placement Financing and Shares for Debt Transaction
12:58p RIVERVIEW FINANCIAL : Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits (form 8-K/A)
12:58p China Natural Resources Releases Interim Results Of Operations
12:57p REPUBLIC SERVICES : Dispose of Christmas trees responsibly
12:57p Food Bank received massive Publix grant
12:56p EXCLUSIVE : Safran, Zodiac deal expected to win unconditional EU approval - source
12:55p DELIVERY HERO AG : Notification and public disclosure of transactions by persons
Latest news "Companies"
Advertisement